
Drug Eluting Balloons (DEBs)
Description
Global Drug Eluting Balloons (DEBs) Market to Reach US$3.4 Billion by 2030
The global market for Drug Eluting Balloons (DEBs) estimated at US$1.8 Billion in the year 2024, is expected to reach US$3.4 Billion by 2030, growing at a CAGR of 11.5% over the analysis period 2024-2030. Peripheral, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Coronary segment is estimated at 14.4% CAGR over the analysis period.
The U.S. Market is Estimated at US$486.8 Million While China is Forecast to Grow at 11.0% CAGR
The Drug Eluting Balloons (DEBs) market in the U.S. is estimated at US$486.8 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$534.7 Million by the year 2030 trailing a CAGR of 11.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.6% and 9.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.
strong>Global Drug Eluting Balloons (DEBs) Market - Key Trends and Drivers Summarized
What Are Drug Eluting Balloons (DEBs) and Why Are They Revolutionary in Medical Treatments?
Drug Eluting Balloons (DEBs) are an innovative class of medical devices used primarily in the treatment of peripheral and coronary artery diseases. These balloons are coated with medication that is delivered directly to the artery`s wall during the angioplasty procedure. Unlike traditional balloon angioplasty that mechanically opens the artery without delivering any therapeutic agents, DEBs provide a dual function: they not only expand the artery to alleviate blockages but also deliver a drug locally to inhibit restenosis (the re-narrowing of the artery). The primary medications used on DEBs are antiproliferative drugs, which help prevent the growth of scar tissue, thus maintaining arterial patency over time and improving patient outcomes significantly.
How Do Drug Eluting Balloons Enhance Clinical Efficacy Compared to Conventional Methods?
The key advantage of drug eluting balloons over traditional treatments lies in their ability to minimize the risk of restenosis and eliminate the need for permanent implants like stents. This is particularly beneficial for patients who may be prone to stent thrombosis or those who have difficulties with long-term antiplatelet therapy. DEBs release medication that inhibits cell proliferation directly at the site of arterial injury caused by the balloon dilation, providing targeted therapeutic action while reducing systemic side effects. This local delivery system ensures a high local drug concentration immediately after the procedure, offering a more effective treatment compared to systemic drug delivery methods.
What Challenges and Innovations Shape the Future of DEBs?
Despite their benefits, the development and usage of DEBs face several challenges. The primary concern is the precision of drug coating and its transfer efficiency during the procedure. Innovations in balloon technology focus on improving the homogeneity and adherence of the drug coating, ensuring that the correct dosage is delivered directly to the arterial wall. Researchers are also exploring biodegradable polymers that can control drug release rates to optimize healing. Regulatory hurdles represent another significant challenge, as the combination of device and drug into a single product requires extensive validation to meet safety and efficacy standards set by health authorities globally.
What Drives the Growth in the Drug Eluting Balloons Market?
The growth in the drug eluting balloons market is driven by several factors, starting with the rising prevalence of cardiovascular diseases worldwide, which increases the demand for effective, minimally invasive treatment options. Advances in materials science have enabled the development of more efficient drug delivery systems on DEBs, enhancing their appeal to interventional cardiologists. The growing body of clinical evidence supporting the efficacy and safety of DEBs compared to conventional therapies is also compelling more healthcare providers to adopt this technology. Furthermore, the desire for treatments that reduce hospital stay durations and improve patient quality of life post-procedure boosts the adoption of DEBs. As healthcare systems increasingly focus on cost-effectiveness and better patient outcomes, the market for drug eluting balloons is expected to continue expanding, fueled by technological innovations and strategic collaborations among key industry players.
SCOPE OF STUDY:The report analyzes the Drug Eluting Balloons (DEBs) market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Product (Peripheral, Coronary); End-Use (Hospitals, Cath Labs, Ambulatory Surgery Centers)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 42 Featured) -
- Acrostak Int. Distr. Sarl
- B. Braun Melsungen AG
- BARD, A Becton, Dickinson Company
- Cardionovum GmbH
- Cook Medical, Inc.
- Eurocor GmbH
- Medtronic PLC
- Spectranetics Corporation
We`re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Drug Eluting Balloons (DEBs) – Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- Global Economic Update
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Growing Incidence of Cardiovascular Diseases Drives Demand for Drug Eluting Balloons (DEBs)
- Increasing Focus on Minimally Invasive Procedures Strengthens Business Case for Drug Eluting Balloons
- Expansion of Peripheral Artery Disease (PAD) Treatment Spurs Demand for DEBs in Vascular Interventions
- Technological Innovations in Biodegradable Polymers Set the Stage for Market Growth in Drug Eluting Balloons
- Rising Adoption of DEBs in Coronary Artery Disease (CAD) Treatment Expands Market Opportunities
- Increasing Use of DEBs in Renal and Carotid Artery Interventions Expands Market Opportunities
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 2: World Historic Review for Drug Eluting Balloons (DEBs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 3: World 15-Year Perspective for Drug Eluting Balloons (DEBs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for Cath Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 5: World Historic Review for Cath Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 6: World 15-Year Perspective for Cath Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 7: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 8: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 9: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 10: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 11: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 12: World 15-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 13: World Drug Eluting Balloons (DEBs) Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Peripheral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Peripheral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Peripheral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Coronary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Coronary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 19: World 15-Year Perspective for Coronary by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- III. MARKET ANALYSIS
- UNITED STATES
- Drug Eluting Balloons (DEBs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 20: USA Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 21: USA Historic Review for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 22: USA 15-Year Perspective for Drug Eluting Balloons (DEBs) by Product - Percentage Breakdown of Value Sales for Peripheral and Coronary for the Years 2015, 2025 & 2030
- TABLE 23: USA Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 24: USA Historic Review for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 25: USA 15-Year Perspective for Drug Eluting Balloons (DEBs) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cath Labs and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
- CANADA
- TABLE 26: Canada Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 27: Canada Historic Review for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 28: Canada 15-Year Perspective for Drug Eluting Balloons (DEBs) by Product - Percentage Breakdown of Value Sales for Peripheral and Coronary for the Years 2015, 2025 & 2030
- TABLE 29: Canada Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 30: Canada Historic Review for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 31: Canada 15-Year Perspective for Drug Eluting Balloons (DEBs) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cath Labs and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
- JAPAN
- Drug Eluting Balloons (DEBs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 32: Japan Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 33: Japan Historic Review for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 34: Japan 15-Year Perspective for Drug Eluting Balloons (DEBs) by Product - Percentage Breakdown of Value Sales for Peripheral and Coronary for the Years 2015, 2025 & 2030
- TABLE 35: Japan Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 36: Japan Historic Review for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 37: Japan 15-Year Perspective for Drug Eluting Balloons (DEBs) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cath Labs and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
- CHINA
- Drug Eluting Balloons (DEBs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 38: China Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 39: China Historic Review for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 40: China 15-Year Perspective for Drug Eluting Balloons (DEBs) by Product - Percentage Breakdown of Value Sales for Peripheral and Coronary for the Years 2015, 2025 & 2030
- TABLE 41: China Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 42: China Historic Review for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 43: China 15-Year Perspective for Drug Eluting Balloons (DEBs) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cath Labs and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
- EUROPE
- Drug Eluting Balloons (DEBs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 44: Europe Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 45: Europe Historic Review for Drug Eluting Balloons (DEBs) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 46: Europe 15-Year Perspective for Drug Eluting Balloons (DEBs) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 47: Europe Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 48: Europe Historic Review for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 49: Europe 15-Year Perspective for Drug Eluting Balloons (DEBs) by Product - Percentage Breakdown of Value Sales for Peripheral and Coronary for the Years 2015, 2025 & 2030
- TABLE 50: Europe Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 51: Europe Historic Review for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 52: Europe 15-Year Perspective for Drug Eluting Balloons (DEBs) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cath Labs and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
- FRANCE
- Drug Eluting Balloons (DEBs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 53: France Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 54: France Historic Review for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 55: France 15-Year Perspective for Drug Eluting Balloons (DEBs) by Product - Percentage Breakdown of Value Sales for Peripheral and Coronary for the Years 2015, 2025 & 2030
- TABLE 56: France Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 57: France Historic Review for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 58: France 15-Year Perspective for Drug Eluting Balloons (DEBs) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cath Labs and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
- GERMANY
- Drug Eluting Balloons (DEBs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 59: Germany Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 60: Germany Historic Review for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 61: Germany 15-Year Perspective for Drug Eluting Balloons (DEBs) by Product - Percentage Breakdown of Value Sales for Peripheral and Coronary for the Years 2015, 2025 & 2030
- TABLE 62: Germany Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 63: Germany Historic Review for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 64: Germany 15-Year Perspective for Drug Eluting Balloons (DEBs) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cath Labs and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
- ITALY
- TABLE 65: Italy Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 66: Italy Historic Review for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 67: Italy 15-Year Perspective for Drug Eluting Balloons (DEBs) by Product - Percentage Breakdown of Value Sales for Peripheral and Coronary for the Years 2015, 2025 & 2030
- TABLE 68: Italy Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 69: Italy Historic Review for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 70: Italy 15-Year Perspective for Drug Eluting Balloons (DEBs) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cath Labs and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
- UNITED KINGDOM
- Drug Eluting Balloons (DEBs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 71: UK Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 72: UK Historic Review for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 73: UK 15-Year Perspective for Drug Eluting Balloons (DEBs) by Product - Percentage Breakdown of Value Sales for Peripheral and Coronary for the Years 2015, 2025 & 2030
- TABLE 74: UK Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 75: UK Historic Review for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 76: UK 15-Year Perspective for Drug Eluting Balloons (DEBs) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cath Labs and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
- REST OF EUROPE
- TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 78: Rest of Europe Historic Review for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 79: Rest of Europe 15-Year Perspective for Drug Eluting Balloons (DEBs) by Product - Percentage Breakdown of Value Sales for Peripheral and Coronary for the Years 2015, 2025 & 2030
- TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 81: Rest of Europe Historic Review for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 82: Rest of Europe 15-Year Perspective for Drug Eluting Balloons (DEBs) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cath Labs and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
- ASIA-PACIFIC
- Drug Eluting Balloons (DEBs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 84: Asia-Pacific Historic Review for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 85: Asia-Pacific 15-Year Perspective for Drug Eluting Balloons (DEBs) by Product - Percentage Breakdown of Value Sales for Peripheral and Coronary for the Years 2015, 2025 & 2030
- TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 87: Asia-Pacific Historic Review for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 88: Asia-Pacific 15-Year Perspective for Drug Eluting Balloons (DEBs) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cath Labs and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
- REST OF WORLD
- TABLE 89: Rest of World Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 90: Rest of World Historic Review for Drug Eluting Balloons (DEBs) by Product - Peripheral and Coronary Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 91: Rest of World 15-Year Perspective for Drug Eluting Balloons (DEBs) by Product - Percentage Breakdown of Value Sales for Peripheral and Coronary for the Years 2015, 2025 & 2030
- TABLE 92: Rest of World Recent Past, Current & Future Analysis for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 93: Rest of World Historic Review for Drug Eluting Balloons (DEBs) by End-Use - Hospitals, Cath Labs and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 94: Rest of World 15-Year Perspective for Drug Eluting Balloons (DEBs) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cath Labs and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
- IV. COMPETITION
Pricing
Currency Rates